Ethers feature bent C–O–C linkages. In dimethyl ether, the bond angle is 111° and C–O distances are 141 pm. 73724-45-5, formula is C18H17NO5, Name is Fmoc-Ser-OH. The barrier to rotation about the C–O bonds is low. The bonding of oxygen in ethers, alcohols, and water is similar. In the language of valence bond theory, the hybridization at oxygen is sp3. SDS of cas: 73724-45-5.
Brousseau, Margaret E.;Clairmont, Kevin B.;Spraggon, Glen;Flyer, Alec N.;Golosov, Andrei A.;Grosche, Philipp;Amin, Jakal;Andre, Jerome;Burdick, Debra;Caplan, Shari;Chen, Guanjing;Chopra, Raj;Ames, Lisa;Dubiel, Diana;Fan, Li;Gattlen, Raphael;Kelly-Sullivan, Dawn;Koch, Alexander W.;Lewis, Ian;Li, Jingzhou;Liu, Eugene;Lubicka, Danuta;Marzinzik, Andreas;Nakajima, Katsumasa;Nettleton, David;Ottl, Johannes;Pan, Meihui;Patel, Tajesh;Perry, Lauren;Pickett, Stephanie;Poirier, Jennifer;Reid, Patrick C.;Pelle, Xavier;Seepersaud, Mohindra;Subramanian, Vanitha;Vera, Victoria;Xu, Mei;Yang, Lihua;Yang, Qing;Yu, Jinghua;Zhu, Guoming;Monovich, Lauren G. research published 《 Identification of a PCSK9-LDLR disruptor peptide with in vivo function》, the research content is summarized as follows. Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma low-d. lipoprotein cholesterol (LDL-C) levels by promoting hepatic LDL receptor (LDLR) degradation Therapeutic antibodies that disrupt PCSK9-LDLR binding reduce LDL-C concentrations and cardiovascular disease risk. The epidermal growth factor precursor homol. domain A (EGF-A) of the LDLR serves as a primary contact with PCSK9 via a flat interface, presenting a challenge for identifying small mol. PCSK9-LDLR disruptors. We employ an affinity-based screen of 1013in vitro-translated macrocyclic peptides to identify high-affinity PCSK9 ligands that utilize a unique, induced-fit pocket and partially disrupt the PCSK9-LDLR interaction. Structure-based design led to mols. with enhanced function and pharmacokinetic properties (e.g., 13PCSK9i). In mice, 13PCSK9i reduces plasma cholesterol levels and increases hepatic LDLR d. in a dose-dependent manner. 13PCSK9i functions by a unique, allosteric mechanism and is the smallest mol. identified to date with in vivo PCSK9-LDLR disruptor function.
SDS of cas: 73724-45-5, Fmoc-Ser-OH, also known as Fmoc-Ser-OH, is a useful research compound. Its molecular formula is C18H17NO5 and its molecular weight is 327.3 g/mol. The purity is usually 95%.
Fmoc-L-Ser-OH is a synthetic peptide that belongs to the group of glycopeptides. It is used as a model for such compounds and has been shown to have antimicrobial activity in vitro against gram-positive bacteria, especially Staphylococcus epidermidis. This compound was synthesized from 3-mercaptopropionic acid and chloride in the presence of hydroxyl groups and epidermal growth factor. The synthetic pathway can be divided into three steps: (1) condensation of 3-mercaptopropionic acid with hydrochloric acid to yield 3-mercaptoacrylic acid; (2) esterification of 3-mercaptoacrylic acid with glycine to form Fmoc-L-Ser; and (3) deprotection of Fmoc protecting group., 73724-45-5.
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem